A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma

被引：2

作者：

Kotb, Rami ^{[1
]}

Gul, Engin ^{[2
]}

Reece, Donna E. ^{[3
,4
]}

机构：

[1] Canc Care Manitoba, Winnipeg, MB, Canada

[2] Canadian Myeloma Res Grp, Toronto, ON, Canada

[3] Canadian Myeloma Res Grp Formerly MCRN, Toronto, ON, Canada

[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-15363

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4767

引用

页数：3

共 50 条

[41] A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study
O'Gorman, Peter
O'Dwyer, Michael E.
Gilligan, Oonagh
Quinn, John
Coyne, Mark
Krawczyk, Janusz
Murphy, Philip T.
McAlester, Lourdes del Rosario
Harraghy, Orna
Cormican, Orlaith
Lenihan, Elizabeth
Egan, Keith
Perera, Meegahage Ratnakanthi
Crotty, Gerard
Hayden, Patrick J.
Hennessy, Brian
O'Leary, Hilary M.
Scott, Kathleen
Parker, Imelda
Cunnane, Michele
Marron, Jacinta
Connell, Aoife
Coghlan, Elizabeth
Laubach, Jacob P.
Richardson, Paul G.
BLOOD, 2016, 128 (22)
[42] Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
Lavoie-Gagnon, Claudie
St-Gelais, Jonathan
Adam, Jean-Philippe
Viens, Daniel
Gagne, Felixe
Decarie, Yann
Lemieux-Blanchard, Emilie
BLOOD, 2017, 130
[43] Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial
Goldschmidt, Hartmut
Mai, Elias K.
Durig, Jan
Scheid, Christof
Weisel, Katja C.
Kunz, Christina
Bertsch, Uta
Hielscher, Thomas
Munder, Markus
Lindemann, Hans-Walter
Huegle-Doerr, Barbara
Hose, Dirk
Seckinger, Anja
Huhn, Stefanie
Jauch, Anna
Rabold, Bernhard
Elmaagacli, Ahmet
Gerecke, Christian
Brossart, Peter
Goerner, Martin
Bernhard, Helga
Hoffmann, Martin
Hillengass, Jens
Raab, Marc-Steffen S.
Blau, Igor Wolfgang
Hanel, Mathias
Salwender, Hans Jurgen
BLOOD, 2017, 130
[44] Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan
Takezako, Naoki
Ohta, Kensuke
Handa, Hiroshi
Hori, Mitsuo
Kinoshita, Gen
Shelat, Suresh
Miyoshi, Masafumi
Kubo, Kohmei
BLOOD, 2017, 130
[45] MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma
Kortuem, M.
Manteca, Mateos M. V.
Grosicki, S.
Kim, K.
Negre, E.
Vandendries, E.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 182 - 182
[46] Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
van Duin, Mark
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk M.
Broijl, Annemiek
Sonneveld, Pieter
BLOOD, 2016, 128 (22)
[47] Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Papaiakovou, Evangelos Eleutherakis
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)
Perrot, Aurore
Lauwers-Cances, Valerie
Touzeau, Cyrille
Decaux, Olivier
Hulin, Cyrille
Macro, Magaret
Stoppa, Anne-Marie
Chretien, Marie Lorraine
Karlin, Lionel
Mariette, Clara
Jacquet, Caroline
Roussel, Murielle
Guillemot, Coralie
Devlamynck, Laure
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
BLOOD, 2021, 138
[49] Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
O'Gorman, Peter
Laubach, Jacob P.
O'Dwyer, Michael E.
Krawczyk, Janusz
Yee, Andrew J.
Gilligan, Oonagh
Cahill, Mary R.
Rosenblatt, Jacalyn
Quinn, John
Murphy, Philip T.
DiPietro, Heidi
Perera, Meegahage Ratnakanthi
Crotty, Gerard M.
Cummings, Kristen
Hayden, Patrick J.
Browne, Paul
Savell, Alexandra
O'Leary, Hilary M.
O'Keeffe, Denis
Masone, Kelly
Hennessy, Brian J.
Garcia, Thomas Guerrero
Scott, Kathleen
Saeed, Khalid
Bianchi, Giada
Dowling, Paul
Tierney, Ciara
Richardson, Paul G.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) : 562 - 573
[50] A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation
Ocio, Enrique M.
Bringhen, Sara
Oliva, Stefania
Rodriguez-Otero, Paula
Kanagavel, Dheepak
Oprea, Corina
Wei, Vivian
Doroumian, Severine
Martinez-Lopez, Joaquin
BLOOD, 2017, 130

← 1 2 3 4 5 →